Your browser doesn't support javascript.
loading
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma.
Rini, Brian I; Brugarolas, James; Atkins, Michael B.
Affiliation
  • Rini BI; Vanderbilt University Medical Center, Nashville, Tennessee, USA brian.rini@vumc.org James.Brugarolas@UTSouthwestern.edu mba41@Georgetown.edu.
  • Brugarolas J; University of Texas Southwestern Department of Internal Medicine, Dallas, Texas, USA brian.rini@vumc.org James.Brugarolas@UTSouthwestern.edu mba41@Georgetown.edu.
  • Atkins MB; Oncology, Georgetown University, Washington, District of Columbia, USA brian.rini@vumc.org James.Brugarolas@UTSouthwestern.edu mba41@Georgetown.edu.
J Immunother Cancer ; 11(3)2023 03.
Article in En | MEDLINE | ID: mdl-36898737
Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Limits: Humans Language: En Journal: J Immunother Cancer Year: 2023 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Limits: Humans Language: En Journal: J Immunother Cancer Year: 2023 Document type: Article Country of publication: United kingdom